[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"occult-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:occult-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100616829","external-validation-of-the-clover-score-for-detecting-occult-cancer-in-venous-thromboembolism-patients-100616829",false,"NCT07310693","External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients","External Validation of a Predictive Model for Occult Cancer Risk in Patients With Venous Thromboembolism Developed Using Machine Learning","CLOVER","Inclusion Criteria:\n\n* Age ≥18 years.\n* Objectively confirmed acute symptomatic venous thromboembolism (deep vein thrombosis and\u002For pulmonary embolism).\n* Ability to provide written or electronic informed consent.\n\nExclusion Criteria:\n\n* Suspicion of cancer during the initial diagnostic evaluation for VTE.\n* Participation in another interventional study that may interfere with outcomes.\n* Inability or refusal to provide informed consent.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","2 Years","OBSERVATIONAL","This study aims to externally validate the CLOVER score, a machine learning-based predictive model designed to identify patients with venous thromboembolism (VTE) who are at increased risk of having an occult cancer. The study includes a retrospective cohort of patients with acute symptomatic VTE diagnosed between 2000 and 2022, and a prospective cohort of consecutively recruited patients from December 2025 to December 2027. The CLOVER model will be applied to all participants, and its ability to discriminate between patients with and without occult cancer will be evaluated. The study also assesses clinicians' satisfaction with the web-based tool (CLOVER-Web) developed to facilitate the use of the score in clinical practice.",[26,27],"Venous Thromboembolism (VTE)","Occult Cancer",[27,29,30,31,32,33],"Venous thromboembolism","Machine learning","Prediction model","External validation","CLOVER score","RECRUITING","2025-12-20",{"date":37,"type":38},"2025-12-30","ACTUAL",{"date":40,"type":38},"2025-12-01",{"date":42,"type":21},"2028-12-31",{"name":44,"class":45},"Infanta Leonor University Hospital","OTHER",12,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100495608","intensive-cancer-screening-after-cryptogenic-stroke-100495608","NCT05733416","Intensive Cancer Screening After Cryptogenic Stroke","Intensive Cancer Screening After Cryptogenic Stroke (INCOGNITO) Pilot Randomized Trial","INCOGNITO","Inclusion Criteria:\n\n* adults ≥18 years\n* presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke)\n* patient or delegate willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* contraindications to FDG PET\u002FCT (pregnancy or unable to lie still in bed for 20 minutes)\n* active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)",{"count":56,"type":21},45,"INTERVENTIONAL",[59],"NA","The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET\u002FCT (F-fluorodeoxyglucose positron emission\u002Fcomputed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.",[27],[63],"cryptogenic stroke","2025-07-29",{"date":66,"type":38},"2025-07-31",{"date":68,"type":38},"2023-09-01",{"date":70,"type":21},"2027-01",{"name":72,"class":45},"Ottawa Hospital Research Institute",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":83,"conditions":84,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":5},"100523823","discovery-of-new-cancer-in-the-1-year-follow-up-after-ischemic-stroke-in-patients-at-risk-the-invisible-1-study-100523823","NCT06100718","Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study","INVISIBLE-1","Inclusion Criteria:\n\n* Informed consent as documented by signature from patient or next of kin\n* Age ≥ 18 years old\n* Acute ischemic stroke with symptom onset within 48 h before admission\n* Acute ischemic stroke with:\n\n  * persistent signs and symptoms of stroke lasting for ≥ 24 hours OR\n  * acute brain infarction documented by computer tomography (CT) or MRI\n* D-dimer ≥ 820 μg\u002FL measured after symptom-onset and within 24h after admission\n* Embolic stroke of unknown source (ESUS)\\* after initial work-up (acute cerebral imaging, 12-lead electrocardiogram, cardiac monitoring for at least 24h and echocardiography)\n\nExclusion Criteria:\n\n* Active cancer\\*\\* known at time of index-stroke\n* Intravenous Thrombolysis administrated prior to D-dimer measurement: Use of external laboratory value possible if available\n* New diagnosis of central nervous system cancer\n* Patient or next of kin (in case of lacking capacity) unlikely to be compliant or available for study follow-up interview\n\nESUS\\*: According to the definition from the NAVIGATE ESUS randomized trial: Non-lacunar ischemic stroke occurring in a patient in whom investigations did not show another specifically treatable underlying stroke etiology, primarily \\>50% stenosis in a proximal extracranial or intracranial artery, atrial fibrillation, other major-risk cardioembolic sources, or other determined etiology.\n\nActive Cancer\\*\\*: According to the definition from the International Society on Thrombosis and Haemostasis: Cancer diagnosed within the previous six months, recurrent, regionally advanced or metastatic cancer, cancer for which treatment had been administered within six months, or hematological malignancy that is not in complete remission for more than 5 years.\n\n► Patients with history of cancer not meeting these criteria anymore can be included in the study.",{"count":82,"type":21},370,"INVISIBLE-1 aims to prospectively follow patients up to one year after ischemic stroke to:\n\n1. Determine the cumulative incidence of occult cancer in patients with embolic stroke of undetermined source (ESUS) and elevated D-dimer\n2. Describe occult cancer characteristics and spontaneous course of occult cancer\n\nMethodology\n\nThe investigators will include 370 stroke patients with elevated D-dimer (≥ 820 μg\u002FL) at the time of stroke, suspicion of ESUS after initial workup and without known cancer. The investigators will perform a follow-up telephone interview at one year to assess the occurrence of a new cancer and characterize the course of the disease.\n\nSignificance\n\nDetermining the real incidence of occult cancer in high-risk patients will help support the implementation of screening trials in the future. Faster detection and treatment of occult cancers would significantly impact patient' outcomes by offering faster cancer treatment and optimal secondary stroke prevention.",[85,86,27,87,88,89],"Cancer-related Stroke","Paraneoplastic Coagulopathy","Ischemic Stroke","Embolic Stroke of Undetermined Source","D-dimer",[91,89,92,93,94],"Cancer-related stroke","ESUS","Occult cancer","Ischemic stroke","2024-12-09",{"date":97,"type":38},"2024-12-13",{"date":99,"type":38},"2022-01-01",{"date":101,"type":21},"2025-12-31",{"name":103,"class":45},"Insel Gruppe AG, University Hospital Bern"]